Publication | Open Access

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

Hematological MalignancyLymphoid NeoplasiaAntisense OligodeoxynucleotideMedicinePathologyPhase Ii StudyAdult T-cell Leukemia-lymphomaOncologyRadiation OncologyCancer ResearchIsis 3521